Bear (PaulWBryant / Drew) Date: 2026-02-22 Quarter: Q4 FY25 (Dec-25) Market cap: ~$28.7B | TTM P/S: ~32x | TTM Revenue: $852.5m
I haven't written about Astera Labs before, so let me be upfront: this is my first application of the framework to ALAB. I'll note where I'm working from first principles vs. established prior views. No position held.
The headline: a genuinely impressive business delivering a clean beat at $270.6m (+92% YoY, +17.5% QoQ), guide of $291.5m midpoint for Q1 FY26. The market disagreed — stock dropped ~20% post-earnings. When that happens, I pay attention. Either the market is wrong, or the market saw something in the details worth understanding.
In this case, I think the market was partially right.
| Metric | Prior Belief | Actual | Assessment |
|---|---|---|---|
| Q4 revenue vs. guide | Beat by 8-11% (consistent pattern) | $270.6m, +8.0% vs. $250.5m guide | Consistent. 4Q avg beat: +9.0% |
| Gross margin | Stable ~76% | 75.6% [GAAP] — and guided 74% Q1 | Worse than expected directionally |
| Scorpio contribution | Growing, possibly 20%+ of Q4 | Scorpio+Taurus = 30% combined | Better than expected on mix; problem is the margin implication |
| Q1 guide | ~$275-285m (extrapolating beat pattern conservatism) | $291.5m midpoint | Guided above what I'd have projected — bullish |
| Operating leverage | Should be improving | Non-GAAP op margin 40.2% — but R&D up $16m QoQ | Flat to slightly down. Investing aggressively. |
| CFO stability | Assumed continuity | Mike Tate departing, Desmond Lynch starts March 2 | Unexpected. Yellow flag. |
| Amazon relationship | Significant customer | 8-K: $6.5B cumulative warrant through 2033 | Formalized — impressive demand floor, but price? |
Delta summary: The beat and Q1 guide are good. The gross margin trajectory and CFO departure are not. The Amazon warrant sounds great until you ask: what margin did they agree to? Volume discounts don't announce themselves in press releases.
| | Q124 | Q224 | Q324 | Q424 | Q125 | Q225 | Q325 | Q425 | | | Mar-24 | Jun-24 | Sep-24 | Dec-24 | Mar-25 | Jun-25 | Sep-25 | Dec-25 | |---|---|---|---|---|---|---|---|---| | Revenue ($m) | 65.3 | 76.9 | 113.1 | 141.1 | 159.4 | 191.9 | 230.3 | 270.6 | | YoY % | 269% | 619% | 207% | 179% | 144% | 150% | 104% | **92%** | | QoQ % | +29% | +18% | +47% | +25% | +13% | +20% | +20% | +18% | | Incr Rev ($m) | +14.8 | +11.6 | +36.2 | +28.0 | +18.3 | +32.5 | +38.4 | +40.3 | | GM % [GAAP] | 78.2% | 78.0% | 77.8% | 74.1% | 74.9% | 76.0% | 76.4% | 75.6% | | Non-GAAP Op Margin | 22.7% | 24.3% | 32.4% | 34.3% | 33.7% | 39.2% | 41.7% | 40.2% | | Net Margin % | 22% | 29% | 36% | 47% | 37% | 41% | 38% | 39% | | Non-GAAP Net Inc ($m) | 14.3 | 22.2 | 40.3 | 66.5 | 59.6 | 78.0 | 88.2 | 104.8 | | Non-GAAP EPS | — | — | — | — | $0.33 | $0.44 | 0.49|**0.58** |
FY25 summary: Revenue $852.5m (+115%). Non-GAAP EPS $1.84 [Non-GAAP]. FCF $281.8m (33.1% FCF margin) [GAAP-adjacent]. SBC $160m = 18.8% of revenue [GAAP].
The YoY deceleration from 144% → 150% → 104% → 92% is mechanical — the comparables are getting harder as FY24 was explosive growth from a tiny base. That's expected and not alarming on its own.
What I track more carefully is sequential dollar adds: $18m → $33m → $38m → $40m. That's healthy acceleration in dollar terms throughout FY25. The business is adding more dollars each quarter.
Then comes Q1 FY26 guidance: 291.5mmidpoint = +20.9m QoQ, or +7.7%. That's a hard stop from +17.5%. Management calls it the normal seasonal pattern. Could be. But apply the 9% average beat factor: actual Q1 could come in at ~$318m if the pattern holds. That would be +17.5% QoQ — back in line with the FY25 trend. In other words, the guide may be deliberately conservative.
I'm not going to invest based on that assumption, but it's worth noting that every single guide over the past year has been materially beatable.
This is where I diverge from a simple "great beat" reading.
Gross margin has been declining: 78.2% → 78.0% → 77.8% → 74.1% → 74.9% → 76.0% → 76.4% → 75.6% [GAAP]. Now guided to ~74% for Q1. The long-run direction is clearly lower.
Why? Scorpio (smart fabric switches) and Taurus (optical cables) are growing from 8% to 30% of revenue in a single year. Switches and cables are hardware-heavy — they carry lower gross margins than Ares retimers (pure silicon, software-adjacent economics). As Scorpio becomes the largest product line (management's own words), this pressure isn't going away.
At 75.6% [GAAP], ALAB still clears my 70% gate with significant headroom. But the direction matters. If margins compress to 70% by FY27, that's a different company economically. The numbers have to match the theory — and the theory here is "platform with expanding margins as software/ecosystem value compounds." The numbers are pointing the other direction.
The Amazon warrant is the X-factor. 6.5Bcumulativethrough2033= 900m/yr average commitment, more than the entire FY25 revenue. That's a real demand floor. But Amazon doesn't sign $6.5B agreements at full list price. Volume pricing means margin compression is baked in at scale. Management gave us no margin guidance on the Amazon relationship. That's a meaningful omission.
Non-GAAP operating margin at 40.2% and FCF margin at 33.1% for FY25 are elite numbers. GAAP profitability is real: $219m net income FY25, $45m in Q4 alone.
Balance sheet is a fortress: $1.19B in cash and securities, zero debt. Current ratio 10.2x. The company is self-funding its R&D expansion (Israel design center, XScale acquisition) from operating cash flow.
SBC at 18.8% of revenue [GAAP] and 47.9% of non-GAAP operating income [GAAP] is elevated. This is a newly-public semiconductor company growing at 100%+, so it's contextually understandable. But it needs to decline as a percentage over the next 2-3 years, or the GAAP/non-GAAP gap stops being a "timing" issue and starts being an economic reality.
I can't review ALAB without addressing Credo (CRDO), because I'd be fooling myself if I didn't. I own CRDO in a meaningful position.
| Metric | ALAB | CRDO |
|---|---|---|
| TTM Revenue | $852.5m | ~$350m |
| Revenue YoY growth | 92% | ~274% |
| P/S (TTM) | ~32x | ~22x |
| Market cap | ~$28.7B | ~$15B |
| Product overlap | Active Electrical Cables (Taurus vs CRDO AECs) | Direct competitors in AECs |
CRDO is growing three times faster at roughly two-thirds the valuation. ALAB has a broader platform (five product families vs. CRDO's focus), which justifies some premium. But at 32x vs. 22x for 3x less growth, ALAB needs to grow into that premium — and the near-term trajectory is pointing the wrong way.
On a pure value-for-growth basis, CRDO is dramatically more attractive right now. I could be wrong — ALAB's TAM ($25B SAM target) is larger and the platform breadth is real. But the numbers have to match the theory, and right now CRDO's numbers match its theory more tightly.
Mike Tate is transitioning to "strategic advisor." Desmond Lynch (ex-Rambus) starts March 2. The phrasing is always "strategic advisor" — that's the soft landing for a departure that wasn't entirely voluntary. I don't know that for certain, but mid-hyper-growth CFO departures deserve scrutiny.
What I'll watch: Does guidance methodology change under Lynch? Does the beat pattern hold? Any restatements or accounting surprises in the first 2-3 quarters under new financial leadership? Lynch comes from Rambus, a smaller but profitable semiconductor company — different scale. The transition risk is real but not disqualifying.
TTM revenue: 852.5m.Marketcap: 28.7B. TTM P/S: ~32x [Non-GAAP].
At 32x revenue, you're paying for a lot of future. Let's think about what "reasonable" looks like. If ALAB grows 60% in FY26 (heroic assumption given Q1 is guiding ~8% QoQ), revenue would be ~$1.36B TTM by year-end. At 20x that revenue (a still-elevated but more normalized multiple), market cap = $27.2B — essentially flat from today. The stock doesn't work on that math unless growth is meaningfully above 60%, or the market re-rates the multiple higher.
For multiple expansion to work at 32x from here, ALAB needs to reaccelerate growth in H2 2026 when Scorpio X ramps. That's the bull case and it's plausible — Scorpio X in production ramp with the Amazon demand floor is a real catalyst. But it's a promise about H2, not current evidence.
I don't invest based on hope. I wait for evidence of the ramp, and then the valuation question becomes: does the opportunity still exist at a higher price?
Positives:
Concerns:
Thesis status (first analysis): Intact but stretched. The secular position is real, the technology differentiation is real, and the execution has been strong. But the valuation requires sustained excellence at a time when margins are compressing and the CFO just left. I'd characterize this as a company I watch closely and would add to on a meaningful pullback — not at 32x after a 20% post-earnings drop that still leaves it rich.
No position — no action at current valuation. If I owned this, I'd hold but not add. The Scorpio X ramp in H2 2026 is worth waiting to see. If that delivers and margins stabilize at 73-75%, the stock earns its premium. If margins slide toward 70% while growth decelerates to 40-50%, the multiple compression will be painful.
I'd revisit at 20-22x TTM revenue (~$18-20B market cap, roughly $100-110/share) where the risk-reward improves significantly.
Balance sheet: $1.19B cash, zero debt. FCF margin 33.1% FY25 [GAAP-adjacent]. SBC 18.8% of revenue [GAAP] — elevated but declining in relative terms.
Bear
"Compound interest is the eighth wonder of the world. He who understands it, earns it; he who doesn't, pays it." — Einstein